- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Boehringer Ingelheim, CarthroniX ink pact to pursue small molecule therapeutics in canine oncology
Under the agreement, Boehringer Ingelheim will test a select group of small molecules provided by CarthroniX with the goal of determining their impact on canine cancers.
Germany: Boehringer Ingelheim and CarthroniX, a biopharmaceutical company have announced that they have entered into a research collaboration to pursue small molecule therapeutics in canine oncology.
"When it comes to the treatment of cancer in dogs, veterinarians have limited therapeutic options compared to other areas. Due to this unmet medical need, Boehringer Ingelheim is committed to oncology research in animal health," the company said in its recent release.
Under the agreement, Boehringer Ingelheim will test a select group of small molecules provided by CarthroniX with the goal of determining their impact on canine cancers.
Read also: Boehringer operating income edges up on Jardiance, animal health
"Cancer is the leading disease-related cause of death in dogs. Current therapies to treat cancer in dogs are often non-specific and sometimes have significant side effects. Therefore, we are searching for new potential therapeutic options to support veterinarians in their care of animals," says Dr. Marlene Hauck, Head of Oncology Research at Boehringer Ingelheim Animal Health. "The impressive work of CarthroniX in developing small molecules could potentially be an effective way to treat cancer."
"We are thrilled to combine our unique molecules with the expertise and reach of the Animal Health division of Boehringer Ingelheim. We see the potential to define a new paradigm in treating canine cancers and thus have major impacts on animal health," says Hassan Serhan, PhD, CEO of CarthroniX.
Carthronix, Inc. is a biopharmaceutical company developing first-in-class small molecules that are designed to control chronic inflammation and harness the regenerative power of the immune system.
Read also: Boehringer Ingelheim, A*STAR ink pact for targeted cancer therapies
Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751